Company: EDSA
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001171843-25-005236
Chunk: 54

Company: Edesa Biotech, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 1
Chunk 54
---
. Expected life of warrants is based on warrant terms. The Company did not and is not expected to declare any dividends. Changes in the subjective input assumptions can materially affect the fair value estimates, and therefore the existing models do not necessarily provide a reliable single measure of the fair value of the Company’s warrants and share options.

Warrants

A summary of the Company’s warrant activity is as follows:

			Number of Warrant Shares (#)

			Weighted Average Exercise Price

			Nine Months Ended June 30, 2025

			Balance - September 30, 2024

			609,717

			$
			21.74

			Issued

			326,560

			3.45

			Expired

			(1,687
			)

			22.40

			Balance - June 30, 2025

			934,590

			$
			15.35

			Nine Months Ended June 30, 2024

			Balance - September 30, 2023

			720,909

			$
			19.51

			Expired

			(111,192
			)

			7.26

			Balance - June 30, 2024

			609,717

			$
			21.74

The weighted average contractual life remaining on the outstanding warrants at June 30, 2025 is 31 months.

12

The following table summarizes information about the warrants outstanding at June 30, 2025:

			Number of Warrants (#)

			Exercise Prices 

			Expiry Dates

			173,614

			$
			10.50

			December 2025

			15,627

			$
			56.00

			February 2026

			27,399

			$
			31.94

			March 2027

			391,390

			$
			24.64

			September 2027

			326,560

			$
			3.45

			October 2029

			934,590

The fair value of warrants granted during the nine months ended June 30, 2024 was estimated using the Black-Scholes option valuation model using the following assumptions:

			Nine Months Ended June 30, 2025